|
TMEM209 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.63091762317435E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.22124532708767E-15 |
| Normal-vs-Stage2 |
7.176500E-03 |
| Normal-vs-Stage3 |
9.10072017745733E-12 |
| Normal-vs-Stage4 |
2.66453525910038E-14 |
| Stage1-vs-Stage2 |
2.732500E-02 |
| Stage1-vs-Stage3 |
3.418800E-01 |
| Stage1-vs-Stage4 |
3.119800E-03 |
| Stage2-vs-Stage3 |
1.245530E-02 |
| Stage2-vs-Stage4 |
2.388100E-04 |
| Stage3-vs-Stage4 |
4.094500E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.33226762955019E-15 |
| Normal-vs-AfricanAmerican |
2.162500E-04 |
| Normal-vs-Asian |
3.07829983725583E-10 |
| Caucasian-vs-AfricanAmerican |
3.312600E-01 |
| Caucasian-vs-Asian |
8.196000E-01 |
| AfricanAmerican-vs-Asian |
4.753200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.37610034478541E-10 |
| Normal-vs-Female |
1.63313806922361E-12 |
| Male-vs-Female |
6.476000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.60329527432168E-11 |
| Normal-vs-Age(41-60Yrs) |
2.89150037247055E-10 |
| Normal-vs-Age(61-80Yrs) |
1.1859000448311E-09 |
| Normal-vs-Age(81-100Yrs) |
4.900300E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.104600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.905800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.415000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.894400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.773800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.798400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.412100E-04 |
| Classical-VS-Follicular |
1.384780E-01 |
| Classical-VS-Other |
1.693160E-01 |
| Classical-VS-Normal |
1.7954526754238E-12 |
| Tall-VS-Follicular |
7.80880000000872E-05 |
| Tall-VS-Other |
9.722800E-01 |
| Tall-VS-Normal |
3.11306536104894E-13 |
| Follicular-VS-Other |
1.043220E-01 |
| Follicular-VS-Normal |
3.22040000000356E-06 |
| Other-VS-Normal |
1.979530E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.77129996518033E-09 |
| Normal-vs-N1 |
1.66688884917221E-12 |
| N0-vs-N1 |
2.023800E-04 |
|
|
